Search
Zilucoplan
go.drugbank.com/drugs/DB15636ApprovedInvestigationalIt is a complement inhibitor that works to prevent the activation of C5, which is a complement protein involved in the innate immune system to initiate inflammatory responses. … [L48701] It was also later approved by the EMA on December 4, 2023, as an add-on treatment for the same condition.[L49131] In July 2024, it was approved by Health Canada for the same indication.
Synonyms: -ASPARTYL-N-METHYL-L-.ALPHA.-ASPARTYL-3-METHYL-, N2-ACETYL-L-LYSYL-L-VALYL-L-.ALPHA.-GLUTAMYL-L-ARGINYL-L-PHENYLALANYL-L-.ALPHA.-ASPARTYL-N-METHYL-L-.ALPHA.-ASPARTYL-3-METHYL-L-VALYL-L-TYROSYL-3-(1H-PYRROLO(2,3-B)PYRIDIN-3-YL)-L-ALANYL-L-.ALPHA.Products: Zılbrysq 16,6 mg/0,416 mL SC Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Enjektör (7 Adet), Zılbrysq 23 mg/0,574 mL SC Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Enjektör (7 Adet)Oxazepam
go.drugbank.com/drugs/DB00842ApprovedOxazepam is an intermediate-acting, 3-hydroxybenzodiazepine used in the treatment of alcohol withdrawal and anxiety disorders. … as compared to other benzodiazepines, and is likely owing in part to oxazepam's relatively simple metabolism.
Categories: Heterocyclic Compounds, 2-RingGlucarpidase
go.drugbank.com/drugs/DB08898ApprovedInvestigationalIn 1983, the gene for carboxypeptidase G2, or glucarpidase, was derived from _Pseudomonas_ sp. strain RS-16 to be cloned into _Escherichia coli_, allowing the enzyme to be produced in sufficient quantities … Glucarpidase is a recombinant carboxypeptidase G2 produced by genetically modified _Escherichia coli_ bacteria. It is a 390-amino acid homodimer protein.
Dalfampridine
go.drugbank.com/drugs/DB06637ApprovedInvestigationalDalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. … FDA approved on January 22, 2010.
Categories: Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 SubstratesSynonyms: 4-AP, 4-AminopyridineMagnesium cation
go.drugbank.com/drugs/DB01378ApprovedInvestigationalNutraceuticalWithdrawnMagnesium hydroxide is used primarily in "Milk of Magnesia", a white aqueous, mildly alkaline suspension of magnesium hydroxide formulated at about 8%w/v. … the bowel, thus stimulating nerves within the colon wall, inducing peristalsis and resulting in evacuation of colonic contents.
Synonyms: Magnesium ion, Magnesium, ion(Mg2+)Mixtures: KALSİMAG-D3 1000 MG/300 MG/880 IU EFERVESAN GRANÜL, 30 ADET, KALSİMAG-D3 1000 MG/300 MG/880 IU EFERVESAN GRANÜL, 40 ADETAlectinib
go.drugbank.com/drugs/DB11363ApprovedInvestigationalIt is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes proliferation of NSCLC … Approved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance
Synonyms: 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrileCategories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, P-glycoprotein inhibitorsLonafarnib
go.drugbank.com/drugs/DB06448ApprovedInvestigationalaberrant farnesylated form of lamin A called progerin in the inner nuclear membrane. … [A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesPertuzumab
go.drugbank.com/drugs/DB06366ApprovedInvestigationalIts indicated conditions have since expanded to include use as both a neoadjuvant therapy and an adjuvant therapy in the treatment of HER2-positive breast cancers at high risk of recurrence. … Pertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (subdomain II) of the human epidermal growth factor receptor 2 protein (HER2).
Mixtures: PHESGO® 600MG/600MG, PHESGO® 600MG/600MGCategories: Receptor, ErbB-2, antagonists & inhibitors, HER2 (Human Epidermal Growth Factor Receptor 2) inhibitorsDequalinium
go.drugbank.com/drugs/DB04209Approved[A249255] It is a quaternary ammonium compound,[L42190] as it consists of an amphipathic cation with two aminoquinaldinium rings at both ends of a long hydrophobic hydrocarbon chain. … [A249255] It is also used in vaginal tablets to treat bacterial vaginosis.[L42190]
Mixtures: EFISOL-C, JASIMENTH C PASTILLESCategories: Heterocyclic Compounds, 2-RingBimekizumab
go.drugbank.com/drugs/DB12917ApprovedInvestigationalBimekizumab is a humanized monoclonal antibody directed towards IL-17, which was approved for use in the EU on August 20, 2021, for the treatment of plaque psoriasis. … [A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment